Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Axsome Therapeutics Inc (AXSM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: AXSM (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 10.93% | Avg. Invested days 34 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.78B USD | Price to earnings Ratio - | 1Y Target Price 173.24 |
Price to earnings Ratio - | 1Y Target Price 173.24 | ||
Volume (30-day avg) 742984 | Beta 1 | 52 Weeks Range 64.11 - 139.13 | Updated Date 03/30/2025 |
52 Weeks Range 64.11 - 139.13 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.99 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -74.47% | Operating Margin (TTM) -51.89% |
Management Effectiveness
Return on Assets (TTM) -27.28% | Return on Equity (TTM) -231.63% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 5657765217 | Price to Sales(TTM) 14.99 |
Enterprise Value 5657765217 | Price to Sales(TTM) 14.99 | ||
Enterprise Value to Revenue 14.67 | Enterprise Value to EBITDA -14.81 | Shares Outstanding 48765400 | Shares Floating 36674021 |
Shares Outstanding 48765400 | Shares Floating 36674021 | ||
Percent Insiders 16.59 | Percent Institutions 77.48 |
Analyst Ratings
Rating 4.71 | Target Price 131.18 | Buy 5 | Strong Buy 12 |
Buy 5 | Strong Buy 12 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Axsome Therapeutics Inc
Company Overview
History and Background
Axsome Therapeutics Inc. was founded in 2012. It is a biopharmaceutical company focused on developing and commercializing novel therapies for central nervous system (CNS) disorders.
Core Business Areas
- CNS Therapies: Developing and commercializing therapies for CNS conditions like depression, Alzheimer's disease agitation, and narcolepsy.
Leadership and Structure
The CEO is Herriot Tabuteau. The company has a typical biopharmaceutical organizational structure with departments for research, development, commercialization, and finance.
Top Products and Market Share
Key Offerings
- AUVELITY: AUVELITY (dextromethorphan HBr and bupropion HCl) is an oral NMDA receptor antagonist with sigma-1 receptor agonist activity indicated for the treatment of major depressive disorder (MDD) in adults. Competitors include SSRIs/SNRIs like Lexapro, Prozac, Zoloft, Cymbalta, and Effexor. Direct market share data is still being established, but AUVELITY's unique mechanism offers a competitive advantage.
- Sunosi: Sunosi (solriamfetol) is a dual-acting dopamine and norepinephrine reuptake inhibitor (DNR). The product is now sold by Jazz Pharmaceuticals (JAZZ) The market share data is no longer directly reported under Axsome Therapeutics, but they received royalties on the sale of Sunosi, so it did contribute to overall revenue. The competitors include stimulants like Adderall and Ritalin.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly the CNS sector, is characterized by high R&D costs, lengthy regulatory approval processes, and strong competition. There is a substantial unmet need for novel and effective therapies for CNS disorders.
Positioning
Axsome is positioning itself as an innovator in CNS therapeutics, focused on developing differentiated products with novel mechanisms of action.
Total Addressable Market (TAM)
The TAM for depression and other CNS disorders is substantial, estimated at billions of dollars annually. Axsome is positioned to capture a portion of this market with its innovative therapies.
Upturn SWOT Analysis
Strengths
- Novel therapeutic candidates
- Experienced management team
- Strategic acquisitions (Sunosi)
- Commercialized product (AUVELITY)
- Strong intellectual property position
Weaknesses
- Reliance on successful clinical trials
- Potential for regulatory setbacks
- Competition from established players
- Financial performance is dependent on the successful commercialization of the products
- Limited revenue streams
Opportunities
- Expansion into new indications
- Partnerships and collaborations
- Acquisition of complementary assets
- Growing prevalence of CNS disorders
- Positive clinical trial results for pipeline candidates
Threats
- Clinical trial failures
- Regulatory delays or rejection
- Competition from generics or biosimilars
- Pricing pressures
- Changes in healthcare policies
Competitors and Market Share
Key Competitors
- LLY
- VRAY
- ALKS
- JAZZ
Competitive Landscape
Axsome's advantage lies in novel mechanisms of action. Disadvantages include limited resources compared to larger pharmaceutical companies.
Major Acquisitions
Sunosi
- Year: 2022
- Acquisition Price (USD millions): 363
- Strategic Rationale: Expanded Axsome's product portfolio with a commercialized product in the CNS space.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by clinical trial progress and regulatory approvals.
Future Projections: Future growth projections depend on the commercial success of AUVELITY, the potential for new product approvals, and strategic partnerships. Analyst estimates can be found on financial websites.
Recent Initiatives: Recent initiatives include the commercial launch of AUVELITY and continued development of pipeline candidates.
Summary
Axsome Therapeutics is a growing biopharmaceutical company with an innovative focus on CNS disorders. The commercial success of AUVELITY is critical to its future. Successful clinical trials for its pipeline products and effective competition with larger pharmaceutical companies will be crucial for continued growth. The company shows promise due to it's innovative approch to drug development and its current and potential product portfolio but relies on its ongoing clinical trials for long term success. A financial assessment shows it has significant potential that matches the high risk associated with such opportunities.
Similar Companies
- LLY
- VRAY
- ALKS
- JAZZ
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Yahoo Finance
- Analyst reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may not be precise. The biopharmaceutical industry is subject to significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Axsome Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2015-11-19 | Founder, Chairman, CEO & President Dr. Herriot Tabuteau M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 683 | Website https://www.axsome.com |
Full time employees 683 | Website https://www.axsome.com | ||
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in developing and delivering novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It is also developing AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor, which has completed Phase III trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation. Axsome Therapeutics, Inc. was incorporated in 2012 and is based in New York, New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.